Caricamento...
Emerging treatment options for patients with high-risk myelodysplastic syndrome
Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis with peripheral blood cytopenias, dysplastic cell morphology, and a variable risk of progression to acute myeloid leukemia (AML). The hypomethylating agents (HMA) azacitidine and d...
Salvato in:
| Pubblicato in: | Ther Adv Hematol |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publications
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7675905/ https://ncbi.nlm.nih.gov/pubmed/33240476 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620720955006 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|